Aixlie Pharmaceuticals today announced that they have obtained the rights to
develop a technology designed by researchers at the Ohio State University.
It is a peptide that appears to regulate an important step in the body's
autoimmune response. Recent pre-clinical research at Ohio State has
indicated that this peptide has the ability to stop the autoimmune
destruction of the myelin sheath in an accepted animal model for multiple
sclerosis. Researchers have shown the peptide is able not only to prevent
the onset of myelin destruction, but also to decrease the process once it
has started. "The first Phase I study for the product is being planned
currently," stated Dr. Gary Pekoe, Aixlie CEO. "We are impressed by the
potential of this technology to impact not only autoimmune neurological
diseases like multiple sclerosis, but foresee its testing in organ
transplant, diabetes, arthritis, and any number of other conditions
involving an autoimmune component."

Aixlie licenses two compounds from Ohio State University Aixlie Pharmaceuticals has obtained the rights to develop a peptide that appears to regulate an important step in the body's autoimmune response, designed by researchers at the Ohio State University.

Click on the 'Back' button to return to the previous screen